<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04342312</url>
  </required_header>
  <id_info>
    <org_study_id>NL70787.068.19</org_study_id>
    <nct_id>NCT04342312</nct_id>
  </id_info>
  <brief_title>Intensive Molecular and Electropathological Characterization of Patients Undergoing Atrial Fibrillation Ablation</brief_title>
  <acronym>ISOLATION</acronym>
  <official_title>Intensive Molecular and Electropathological Characterization of patientS undergOing atriaL fibrillATion ablatION: a Multicenter Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Although there are several individual factors which are known to influence the chances of
      successful atrial fibrillation (AF) ablation, it remains a challenge to identify patients at
      risk for ablation failure with satisfactory certainty.

      Objectives:

      To identify predictors of success of AF ablation including clinical factors, AF recurrence
      patterns, anatomical and electrophysiological characteristics, circulating biomarkers and
      individual genetic background.

      Study design:

      Prospective registry of patients undergoing AF ablation. Clinical characteristics and results
      of routine tests are collected. In addition, the following (non-standard) tests are
      performed: extended surface electrocardiogram (extECG), extended rhythm monitoring, biomarker
      testing, genetic analysis, questionnaires. In subgroups of patients transesophageal
      electrocardiogram (TE-ECG), epicardial electroanatomical mapping and/or left atrial appendage
      (LAA) biopsy is performed.

      Study population:

      Patients aged 18 years and older with documented AF, scheduled for AF ablation.

      Main study endpoints:

      Ablation success after 12 and 24 months, defined as freedom from any episode of documented
      atrial arrhythmia after the blanking period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ablation success</measure>
    <time_frame>12 months</time_frame>
    <description>Ablation success is defined as freedom from documented recurrence of atrial arrhythmia after 12 months. Recurrences in the first 3 months after the index procedure (blanking period) are exempted.
Atrial arrhythmias are AF, atrial tachycardia (AT) and non-isthmus dependent atrial flutter (AFl), lasting more than 30 seconds, documented on ECG or Holter monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of AF or atrial arrhythmia after the blanking period</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early recurrences of AF or atrial arrhythmia, defined as any episode of AF AT or non-isthmus dependent AFl during the blanking period.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease progression to persistent or permanent AF.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating biomarkers and non-invasive electrophysiological markers for substrate quantification.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiarrhythmic drugs (AADs) one year after ablation.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of veins with pulmonary vein reconnection at redo procedure.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation Paroxysmal</condition>
  <condition>Atrial Fibrillation, Persistent</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary vein isolation</intervention_name>
    <description>Participation in this study does not influence the choice of ablation technique. Usually, cryoballoon ablation is chosen for patients with paroxysmal AF and no previous ablations. Radiofrequency ablation is often used for redo procedures or for patients with persistent AF. Hybrid ablations are most applied in persistent AF patients. However, physicians may deviate from these standard approaches for a variety of reasons, including personal experience or preference.</description>
    <other_name>atrial fibrillation ablation</other_name>
    <other_name>AF ablation</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All eligible patients scheduled for AF ablation of at the MUMC+ and Radboudumc will be
        asked to participate in this cohort study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older;

          -  Documented atrial fibrillation;

          -  Scheduled for AF ablation or redo AF ablation;

          -  Able and willing to provide written informed consent.

        Exclusion criteria

          -  Serious patient condition before ablation;

          -  Physically or mentally unable to provide written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Schotten, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht University, departments of physiology and cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Vernooy, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Maastricht UMC+ and Radboudumc, department of cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique VM Verhaert, MD</last_name>
    <phone>+31 24 30 92470</phone>
    <email>dominique.verhaert@radboudumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA Nijmegen</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique VM Verhaert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique VM Verhaert, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 8, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Vein Isolation</keyword>
  <keyword>Cryoballoon ablation</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

